Lepu Scientech Medical Technology (Shanghai) Co. Ltd. raised HK$567 million (US$72.2 million) in a Hong Kong initial public offering. Its shares opened at HK$29.8 apiece, increased over 2% in the middle of the day and closed at HK$29.15 on Nov. 8.
Sensorium Therapeutics Inc. closed a $30 million series A round to fund the discovery and development of new psychiatric drugs, inspired by human ethnobotanical practices that date back hundreds or even thousands of years.
Zhuhai Beihai Biotech Co. Ltd. has raised nearly ¥200 million (US$27.5 million) in a series B round slated to support clinical trials for its lead candidates as well as preparations to file an NDA for its core asset, BH-009.
Predictive analytics startup Intus Care Inc. scooped up $14.1 million in a series A round led by Deerfield Management. The funds will be used to advance and scale its software platform for geriatric care.
Biopharma financings in 2022 are now tracking 12% higher than the pre-pandemic year of 2019, but they still pale in comparison with each of the last two years, both of which were standout years by every measure.